Mark Shackleton
Overview
Explore the profile of Mark Shackleton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
83
Citations
7233
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Gaughran G, Zalcberg J, Hawkins C, Shackleton M, Voskoboynik M
Asia Pac J Clin Oncol
. 2021 Jul;
17(4):416-417.
PMID: 34291568
No abstract available.
22.
Robertson S, Orme L, Teixeira R, Shamassi M, Newell F, Patch A, et al.
JAMA Dermatol
. 2021 Jun;
157(7):836-841.
PMID: 34076666
Importance: Spitz nevi are benign melanocytic neoplasms that classically present in childhood. Isolated Spitz nevi have been associated with oncogenic gene fusions in approximately 50% of cases. The rare agminated...
23.
Vergara I, Mintoff C, Sandhu S, Mcintosh L, Young R, Wong S, et al.
Nat Commun
. 2021 Mar;
12(1):1434.
PMID: 33664264
Although melanoma is initiated by acquisition of point mutations and limited focal copy number alterations in melanocytes-of-origin, the nature of genetic changes that characterise lethal metastatic disease is poorly understood....
24.
Blood Z, Tran A, Caleo L, Saw R, Dieng M, Shackleton M, et al.
BMJ Open
. 2021 Feb;
11(2):e040751.
PMID: 33574144
Objectives: To identify patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs) in clinical quality registries, for people with cutaneous melanoma, to inform a new Australian Melanoma Clinical Outcomes Registry;...
25.
Berry W, Tan K, Haydon A, Shackleton M, Mar V
Aust J Gen Pract
. 2021 Feb;
50.
PMID: 33543153
As the COVID-19 pandemic has reduced face-to-face medical consultations, reduced diagnoses of thin melanomas and delayed presentations of thick melanomas were anticipated.
26.
Bhave P, Pallan L, Long G, Menzies A, Atkinson V, Cohen J, et al.
Br J Cancer
. 2020 Oct;
124(3):574-580.
PMID: 33087895
Background: Adjuvant targeted therapy (TT) improves relapse free survival in patients with resected BRAF mutant stage III melanoma. The outcomes and optimal management of patients who relapse after adjuvant TT...
27.
Byron Y, Nott L, Shackleton M
Melanoma Res
. 2020 Sep;
30(6):625-627.
PMID: 32976221
No abstract available.
28.
Lynch F, Katona L, Jefford M, Smith A, Shaw J, Dhillon H, et al.
J Clin Med
. 2020 Sep;
9(9).
PMID: 32937942
Immunotherapies and targeted therapies have revolutionised treatment of metastatic melanoma and improved survival rates. However, survivors treated with novel therapies are vulnerable to high levels of fear of cancer recurrence...
29.
Samuel E, Lie G, Balasubramanian A, Hiong A, So Y, Voskoboynik M, et al.
Clin Lung Cancer
. 2020 Aug;
22(3):e425-e430.
PMID: 32778511
Background: The impact of radiotherapy (RT) on the efficacy and toxicity of immune checkpoint inhibitors (ICIs) in patients with metastatic non-small-cell lung cancer (NSCLC) is unclear. Materials And Methods: We...
30.
Dall G, Vieusseux J, Seyed-Razavi Y, Godde N, Ludford-Menting M, Russell S, et al.
Breast Cancer Res Treat
. 2020 Jul;
183(3):565-575.
PMID: 32696317
Background: Breast cancer (BCa) mortality is decreasing with early detection and improvement in therapies. The incidence of BCa, however, continues to increase, particularly estrogen-receptor-positive (ER +) subtypes. One of the...